for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Inovio Pharmaceuticals, Parker Institute For Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

Jan 9 (Reuters) - Inovio Pharmaceuticals Inc:

* INOVIO PHARMACEUTICALS AND THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY ESTABLISH CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE NOVEL CANCER IMMUNOTHERAPY COMBINATIONS

* INOVIO PHARMACEUTICALS - UNDER AGREEMENT, PARKER INSTITUTE WILL HAVE RESPONSIBILITY FOR CLINICAL STUDY EXECUTION

* INOVIO PHARMACEUTICALS - WILL PROVIDE FINANCIAL CONTRIBUTIONS IF CO’S PRODUCT(S) STUDIED UNDER COLLABORATION REACHES INITIATION OF PHASE 3 STUDY Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up